These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 20140106)

  • 21. VKORC1 and CYP2C9 genotypes in Egyptian patients with warfarin resistance.
    Azzam H; Elwakeel H; Awad I; El-Farahaty R; El-Gilany AH; El-Sharawy S
    Blood Coagul Fibrinolysis; 2016 Mar; 27(2):121-6. PubMed ID: 24978953
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased frequency of CYP2C9 variant alleles and homozygous VKORC1*2B carriers in warfarin-treated patients with excessive INR response.
    Molden E; Okkenhaug C; Ekker Solberg E
    Eur J Clin Pharmacol; 2010 May; 66(5):525-30. PubMed ID: 20354686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Testing of VKORC1 and CYP2C9 alleles to guide warfarin dosing. Test category: pharmacogenomic (treatment).
    Grossniklaus D
    PLoS Curr; 2010 Sep; 2():. PubMed ID: 20877452
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of UDP-Glucuronosyltransferase Polymorphisms on Stable Warfarin Doses in Patients with Mechanical Cardiac Valves.
    An SH; Chang BC; Lee KE; Gwak HS
    Cardiovasc Ther; 2015 Dec; 33(6):324-8. PubMed ID: 26223945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of CYP2C9 and VKORC1 genetic polymorphisms upon warfarin dose requirements in Egyptian patients with acute coronary syndrome.
    Ghozlan MF; Foad DA; Darwish YW; Saad AA
    Blood Coagul Fibrinolysis; 2015 Jul; 26(5):499-504. PubMed ID: 25699611
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Impact of pharmacogenetics on interindividual variability in the response to vitamin K antagonist therapy].
    Siguret V
    Pathol Biol (Paris); 2007 Jul; 55(6):295-8. PubMed ID: 17611042
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The bleeding risk during warfarin therapy is associated with the number of variant alleles of CYP2C9 and VKORC1 genes.
    Tomek A; Maťoška V; Kolářová T; Neumann J; Srámek M; Sarbochová I; Táborský L; Bojar M; Goetz P; Serebruany VL
    Cardiology; 2013; 125(3):182-91. PubMed ID: 23774101
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of combinatorial CYP2C9 and VKORC1 genotypes in Puerto Ricans: implications for warfarin management in Hispanics.
    Duconge J; Cadilla CL; Windemuth A; Kocherla M; Gorowski K; Seip RL; Bogaard K; Renta JY; Piovanetti P; D'Agostino D; Santiago-Borrero PJ; Ruaño G
    Ethn Dis; 2009; 19(4):390-5. PubMed ID: 20073138
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacogenetics-Based Warfarin Dosing in Patients With Cardiac Valve Replacement: The Effects of CYP2C9 and VKORC1 Gene Polymorphisms.
    Farzamikia N; Sakhinia E; Afrasiabirad A
    Lab Med; 2017 Dec; 49(1):25-34. PubMed ID: 29182754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Possible application of pharmacogenomics to warfarin therapy].
    Murata M
    Rinsho Byori; 2011 Jun; 59(6):594-7. PubMed ID: 21815482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. VKORC1 polymorphisms and warfarin maintenance dose in population of Sakha (Yakuts).
    Chertovskikh YV; Malova EU; Maksimova NR; Popova NV; Sychev DA
    Int J Risk Saf Med; 2015; 27 Suppl 1():S17-8. PubMed ID: 26639691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Genetic risk assessment towards warfarin application: Saudi Arabia study with a potential to predict and prevent side effects.
    Al-Saikhan FI
    Saudi J Biol Sci; 2020 Jan; 27(1):456-459. PubMed ID: 31889870
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Contribution of
    Khaleqsefat E; Khalaj-Kondori M; Jabarpour Bonyadi M; Soraya H; Askari B
    Iran J Pharm Res; 2020; 19(3):77-85. PubMed ID: 33680011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of CYP2C9, VKORC1, and CYP4F2 polymorphisms on warfarin maintenance dose in children aged less than 18 years: a protocol for systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Brandão LR; Ito S
    Syst Rev; 2016 Jun; 5(1):105. PubMed ID: 27334984
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of Pregnane X Receptor Genetic Polymorphisms on Stable Warfarin Doses.
    Moon JY; Chang BC; Lee KE; Bang JS; Gwak HS
    J Cardiovasc Pharmacol Ther; 2015 Nov; 20(6):532-8. PubMed ID: 25848132
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dosing algorithm for warfarin using CYP2C9 and VKORC1 genotyping from a multi-ethnic population: comparison with other equations.
    Wu AH; Wang P; Smith A; Haller C; Drake K; Linder M; Valdes R
    Pharmacogenomics; 2008 Feb; 9(2):169-78. PubMed ID: 18370846
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Variability of warfarin dose response associated with CYP2C9 and VKORC1 gene polymorphisms in Chinese patients.
    Ye C; Jin H; Zhang R; Sun Y; Wang Z; Sun W; Sun W; Peng Q; Liu R; Huang Y
    J Int Med Res; 2014 Feb; 42(1):67-76. PubMed ID: 24287930
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification and Enzymatic Activity Evaluation of a Novel
    Zhou XY; Lu XR; Li YH; Ma YQ; Zhao SW; Wang F; Xu RA; Hu GX; Cai JP
    Front Pharmacol; 2021; 12():619339. PubMed ID: 33643050
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.
    Takeuchi M; Kobayashi T; Biss T; Kamali F; Vear SI; Ho RH; Bajolle F; Loriot MA; Shaw K; Carleton BC; Hamberg AK; Wadelius M; Hirono K; Taguchi M; Wakamiya T; Yanagimachi M; Hirai K; Itoh K; Brandão LR; Ito S
    Pharmacogenomics J; 2020 Apr; 20(2):306-319. PubMed ID: 31673144
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.